Trial Profile
Biomarkers Impact on the Response to Treatment With Erlotinib in First Line Non-small Cell Lung Cancer With EGFR Activating Mutations - BIOTEC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BIOTEC
- Sponsors Roche
- 31 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Dec 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.